Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25830865 | 0.98 | KMT2A (0.51) | KMT2AMEN1CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL24673728 | 0.98 | KMT2A (0.51) | KMT2AMEN1CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL24764568 | 0.95 | KMT2A (0.45) | KMT2AMEN1CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL21105779 | 0.95 | KMT2A (0.46) | KMT2AMEN1CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL23807051 | 0.92 | KMT2A (0.49) | KMT2AMEN1CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL22837695 | 0.91 | KMT2A (0.58) | KMT2AMEN1CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL21106165 | 0.89 | KMT2A (0.61) | KMT2AMEN1CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL18908752 | 0.89 | KMT2A (0.61) | KMT2AMEN1CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL21106234 | 0.89 | KMT2A (0.61) | KMT2AMEN1CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL18908759 | 0.89 | KMT2A (0.61) | KMT2AMEN1CYP2D6CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KMT2A 445/4885MEN1 4055/4885CYP2D6 3599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.